Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > IMVT Immunovant > Detailed Quotes

IMVT Immunovant

4.880
-0.250-4.87%
Close 09/23 16:00 ET
4.8800.0000.00%
Post Mkt Price 09/23 16:01 ET
High
5.090
Open
5.050
Turnover
1.35M
Low
4.680
Pre Close
5.130
Volume
278.68K
Market Cap
568.90M
P/E(TTM)
Loss
52wk High
9.535
Shares
116.58M
P/E(Static)
Loss
52wk Low
3.145
Float Cap
162.60M
Bid/Ask %
0.00%
Historical High
53.750
Shs Float
33.32M
Volume Ratio
0.75
Historical Low
3.145
Dividend TTM
--
Div Yield TTM
--
P/B
1.30
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.84%
Amplitude
7.99%
Avg Price
4.847
Lot Size
1
Float Cap
162.60M
Bid/Ask %
0.00%
Historical High
53.750
Shs Float
33.32M
Volume Ratio
0.75
Historical Low
3.145
Dividend TTM
--
P/B
1.30
Dividend LFY
--
Turnover Ratio
0.84%
Amplitude
7.99%
Avg Price
4.847
Lot Size
1
Price Forecast

No Data

News

Comment

Sign in to post a comment

No comment yet

Company Overview More
Immunovant, Inc. is a clinical-stage biopharmaceutical company. The firm focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded in 2018 and is headquartered in New York, NY.
CEO: Dr. Peter Salzmann, M.B.A.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...